Source of proband ascertainment | San Franciscoa | Ontario | Melbourne and Sydney | New York | Philadelphia | Utah | Total |
---|---|---|---|---|---|---|---|
Population-based case probands | Â | Â | Â | Â | Â | Â | 6126 |
   Female, with first primary breast cancer | 2038 | 2553 | 1141 |  |  |  | 5732 |
   Female, with second breast cancer | 199 | 91 | 0 |  |  |  | 290 |
   Male | 56 | 48 | 0 |  |  |  | 104 |
Population-based control probands | Â | Â | Â | Â | Â | Â | 2990 |
   Female | 634 | 1711 | 645 |  |  |  | 2990 |
Clinic-based affected probands | Â | Â | Â | Â | Â | Â | 1647 |
   Female, with first primary breast cancer | 0 | 333 | 177 | 574 | 241 | 54 | 1379 |
   Female, with second breast cancer | 0 | 27 | 15 | 152 | 34 | 20 | 248 |
   Male | 0 | 3 | 1 | 14 | 2 | 0 | 20 |
Clinic-based unaffected probands | Â | Â | Â | Â | Â | Â | 1187 |
   Female | 0 | 0 | 179 | 386 | 489 | 109 | 1163 |
   Male | 0 | 0 | 2 | 8 | 14 | 0 | 24 |
Total probands | 2927 | 4766 | 2160 | 1134 | 780 | 183 | 11,950 |
   Female, with first primary breast cancer | 2038 | 2886 | 1318 | 574 | 241 | 54 | 7111 |
   Female, with second breast cancer | 199 | 118 | 15 | 152 | 34 | 20 | 538 |
   Female, without breast cancer | 634 | 1711 | 824 | 386 | 489 | 109 | 4153 |
   Male, with breast cancer | 56 | 51 | 1 | 14 | 2 | 0 | 124 |
   Male, without breast cancer | 0 | 0 | 2 | 8 | 14 | 0 | 24 |